

20. Osipenko ON, Tate RJ, Gurney AM 2000 Potential role for kv3.1b channels as oxygen sensors. *Circ Res* 86:534–540
21. Sato K, Morio Y, Morris KG, Rodman DM, McMurtry IF 2000 Mechanism of hypoxic pulmonary vasoconstriction involves ET(A) receptor-mediated inhibition of K(ATP) channel. *Am J Physiol Lung Cell Mol Physiol* 278:L434–L442
22. Wang Z, Lanner MC, Jin N, Swartz D, Li L, Rhoades RA 2003 Hypoxia inhibits myosin phosphatase in pulmonary arterial smooth muscle cells: role of Rho-kinase. *Am J Respir Cell Mol Biol* 29:465–471
23. Gao Y, Raj JU 2005 Role of veins in regulation of pulmonary circulation. *Am J Physiol Lung Cell Mol Physiol* 288:L213–L226
24. Bush A 2006 Update in pediatrics 2005. *Am J Respir Crit Care Med* 173:585–592
25. Janssen LJ, Catali A, Helli P 2005 The pulmonary biology of isoprostanes. *Antioxid Redox Signal* 7:244–255
26. Janssen LJ, Premji M, Netherton S, Coruzzi J, Lu-Chao H, Cox PG 2001 Vasoconstrictor actions of isoprostanes via tyrosine kinase and Rho kinase in human and canine pulmonary vascular smooth muscles. *Br J Pharmacol* 132:127–134
27. Faraci FM, Didion SP 2004 Vascular protection: superoxide dismutase isoforms in the vessel wall. *Arterioscler Thromb Vasc Biol* 24:1367–1373
28. Haddad IY, Ischiropoulos H, Holm BA, Beckman JS, Baker JR, Matalon S 1993 Mechanisms of peroxynitrite-induced injury to pulmonary surfactants. *Am J Physiol* 265:L555–L564
29. Belik J, Jankov RP, Pan J, Tanswell AK 2004 Peroxynitrite inhibits relaxation and induces pulmonary artery muscle contraction in the newborn rat. *Free Radic Biol Med* 37:1384–1392
30. Oishi P, Grobe A, Benavidez E, Ovadia B, Harmon C, Ross GA, Hendricks-Munoz K, Xu J, Black SM, Fineman JR 2006 Inhaled nitric oxide induced NOS inhibition and rebound pulmonary hypertension: a role for superoxide and peroxynitrite in the intact lamb. *Am J Physiol Lung Cell Mol Physiol* 290:L359–L366
31. Liu JQ, Zelko IN, Erbynn EM, Sham JS, Folz RJ 2006 Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox). *Am J Physiol Lung Cell Mol Physiol* 290:L2–L10

Erratum

The article “Synergistic Protection of a general Caspase Inhibitor and MK-801 in Bilirubin-Induced Cell Death in Human NT2-N neurons”, by Erik Hankø, et al. (*Pediatr Res* 59:72–77) contained errors. Re-calculations did not change the principal conclusions, but the following errors are corrected:

In the abstract, the paragraph “zVAD.FMK (100 μ M only) reduced . . . differences after 48 h” should read: “zVAD.FMK enhanced neuronal survival by reducing apoptotic nuclear fragmentation, while MK-801 enhanced survival by reducing apoptotic nuclear condensation; both without affecting the MTT assays. Combined treatment reduced both apoptotic morphologies (without affecting necrosis), and this effect was also reflected in the MTT assays.”

Page 74, left column, second paragraph, the sentence beginning “The two different caspases” should read: “zVAD.FMK significantly enhanced neuronal survival, while zDEVD.FMK had no such effect.”

Page 74, left column, second paragraph, the sentence beginning “Both caspase inhibitors” should read: “zDEVD.FMK significantly enhanced the proportion of condensed nuclei (after 24 h).”

Page 74, right column, second paragraph, the sentence beginning “MK-801 significantly reduced” should read: “MK-801 enhanced the proportion of undamaged nuclei at 48 h, but did not significantly enhance MTT reduction.”

The authors regret the errors. A set of corrected figures is available in PDF format from Erikh@ulrik.uio.no.